• 'The numbers don't lie': Endoscopy to become more prominent among next generation of spine surgeons
  • Minnesota orthopedic group hit with $111M negligence verdict
  • Orthopedic patient's death highlights potential dangers of prior authorization
  • Spine surgeon killed in Oklahoma hospital shooting
  • Neurosurgeon accepted $3.3M in illegal payments to perform spine surgeries at hospital
  • Spine surgeon gets jail time for abusing patient during hospital visit
  • Providence to pay $22.7M to settle unnecessary spine surgery allegations
  • Texas spine surgeon defending himself from 'Dr. Death 2.0' allegations
  • 'They're on really thin ice': Why 1 insurer has drawn spine surgeons' ire
  • Orthopedic surgeon must face suit in patient's death
  • Spine surgeon 1 of 9 physician billionaires on Forbes' 2022 list
  • Connecticut hospital to appeal $12.5M verdict to family of patient who died after orthopedic surgery
  • 4 spine technologies that promised more than they delivered
  • Orthopedic surgeon's health system exit steeped in controversy
  • Terminated orthopedic surgeon contracts with another New York hospital
  • Texas spine surgeon sued by State Farm over 'unnecessary' procedures
  • 22 hospitals ranked top 25 orthopedic hospitals 3+ years in a row
  • Orthopedic surgeon convicted of battery at hospital
  • UArizona neurosurgery chair dies after motorcycle collision
  • America's largest independent practices by number of spine surgeons
  • Could Medtronic's spine business be the next medtech spinoff?
  • 41 'rising stars' in orthopedics
  • Idaho orthopedic surgeon arrested for alleged misconduct at practice
  • Neurosurgeon's startup hits $1.2B valuation
  • Orthopedic surgeon indicted in $10M telemedicine fraud scheme
  • Orthopedic surgeon salaries in the 5 best, worst states for healthcare
  • New Jersey hospital must pay neurosurgeons $24.3M, appeals court rules
  • Good news, bad news for orthopedic surgeons: 6 observations
  • Why private equity is bettering orthopedics, 3 physician leaders say
  • Florida hospital patients say they were injured during surgeries. Now a physician faces 350 lawsuits.
  • Texas spine surgeon's $11M verdict being appealed
  • A Rutgers physician accused of 'ghost surgeries' will return — but with fewer responsibilities
  • Top orthopedic hospital in every state: US News
  • Rothman Orthopaedics to become national brand, but no 'aspirations to go beyond US'
  • Sports medicine physician fired amid misconduct allegations involving patients
  • Orthopedic surgeon asking for misconduct charges to be dropped
  • Unnecessary spine cases spur class action lawsuit
  • Colorado Supreme Court rejects hospital's bid to enforce $229K spine surgery bill
  • Jury finds neurosurgeon largely responsible for paralysis, awards $15.5M in damages
  • Dr. Jon Yoon performs NHL's 4th disc replacement in 7 months
  • Stem cells in spine, orthopedics: 6 notes for surgeons

    Stem cells in spine, orthopedics: 6 notes for surgeons

    Alan Condon -  

    A landmark clinical trial was announced in November when a $9 million grant was provided for the first human study using stem cells to treat a spinal disorder that occurs in babies in the womb.

    Becker's Spine Review expands on this clinical trial and five other stem cell notes from this year, including insights from leading spine and orthopedic surgeons. 

    1. The California Institute for Regenerative Medicine provided a $9 million grant to fund the first human clinical trial using stem cells to treat spina bifida. The grant was awarded to researchers at UC Davis Health in Sacramento, Calif. Beginning in 2021, the clinical trial will administer stem cells derived from placental tissue to babies in the womb to repair the defect that occurs when the protective tissue around a baby's developing spinal cord fails to fully close before birth.

    2. The Steadman Philippon Research Institute in Vail, Colo., received a grant from the National Institutes of Health in August to study the use of bone marrow stem cells to delay osteoarthritis in the knee. More than $2.8 million may be awarded to SPRI as part of NIH's Regenerative Medicine Innovation Project, which aims to accelerate clinical stem cell research. Enrollment for the clinical trials will begin this fall.

    3. In August, biopharmaceutical company DiscGenics raised $50 million, which it is using to fund clinical trials of its allogeneic, injectable disc cell therapy for lumbar degenerative disc disease. Discogenic Cells, biomedically engineered progenitor cells derived from human intervertebral disc tissue, are the active ingredient in IDCT. DiscGenics has secured more than $71 million in funding to date.

    4. Most stem cell research is being conducted in animals, but many clinical trials have shown potential for spine surgery, according to Eeric Truumees, MD, president of the North American Spine Society. One interesting area "involves growing out cells on a scaffold and then surgically implanting the tissue into the spine," which could lead to shifts in the management of spinal cord injury and intervertebral disc regeneration, he said.

    Many stem cell and regenerative medicine clinics have opened in the U.S., typically using cells from the iliac crest or platelet-rich plasma, and often as part of well-regarded spine practices, according to Dr. Truumees. While there are many testimonials about the efficacy of these products, the peer-reviewed evidence remains limited. Stem cell-based therapies may have a big future in orthopedics, but presently it's too soon to say, he said. 

    5. Stem cells in orthopedics and spine surgery are more hype than reality, according to Neel Anand, MD, professor of orthopedic surgery and director of spine trauma at the Cedars-Sinai Spine Center in Los Angeles. Many patients seek out these highly marketed stem cell injections, which can cost thousands of dollars out of pocket, Dr. Anand said. In an interview with Becker's, he questioned the ethical side of providing these injections, which he considers experimental, rather than therapeutic. 

    6. The orthopedic industry is in the midst of a stem cell bubble, which could soon burst as researchers realize there's a lot more research that needs to be done, according to Adam Anz, MD, director of the Andrews Institute Regenerative Medicine Center in Gulf Breeze, Fla. Other products such as bone marrow aspirate and PRP have shown promise for the treatment of osteoarthritis. PRP has the largest body of work to "support its use for osteoarthritis" but BMA and other products still have some work to do to prove their value, Dr. Anz said. 

    Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

    Featured Webinars

    Featured Podcast

    Featured Whitepapers